The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

317 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-06

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pancreatic Cancer Serum and DNA Repository

NCT00296114

Pancreas Cancer

COMPLETED

Pancreatic Cancer Registry: For Any Person With a Personal or Family History

NCT02886247

Pancreatic Cancer, ATM, BRCA, Hereditary Cancer

RECRUITING

Identification of Biomarkers for Early Detection of Pancreatic Cancer

NCT00897494

Pancreatic Cancer

COMPLETED

Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center

NCT06712797

Pancreatic Ductal Adenocarcinoma Intraductal Papillary Mucinous Neoplasm

RECRUITING NA

Pancreatic Adenocarcinoma Gene Environment Risk Study

NCT00912717

Pancreatic Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Ductal Adenocarcinoma Pancreatic Cyst Chronic Pancreatitis Fatty Pancreas Genetic Pancreatic Cancer Genetic Pancreatitis BRCA Mutation Lynch Syndrome FAP Familial Atypical Multiple Mole-Melanoma PALB2 Gene Mutation Peutz-Jeghers Syndrome Ataxia Telangiectasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All participants

Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic.

Data collection

Intervention Type OTHER

Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data collection

Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older
* Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)
* Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.
* Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes